Latest Conference Articles

Treatment with the PD-L1 inhibitor avelumab demonstrated promising overall response rates for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Premenopausal women with high-risk breast cancer of the luminal A subtype derive no benefit from adjuvant chemotherapy.

A follow-up analysis of the benefits of adding denosumab to aromatase inhibitor therapy has found that the agent not only helps to prevent fractures, it reduces the risk of recurrence and death in postmenopausal women with HR-positive breast cancer.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, director, Clinical and Translational Cancer Research, discusses an upcoming event at John Theurer Cancer Center in honor of the institution's 25th anniversary of its first bone marrow transplant.

Adding capecitabine to adjuvant therapy reduced the risk of disease recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer following neoadjuvant chemotherapy and surgery.

Monotherapy with blinatumomab demonstrated high complete remission or CR with partial hematological recovery rates in adult patients with Philadelphia chromosome-positive and -negative B-cell precursor acute lymphoblastic leukemia.

Two CD19-targeted chimeric antigen receptor-modified T-cell therapies demonstrated complete response rates ranging from 90% to 100% in patients with high-risk acute lymphoblastic leukemia.

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses results of the RESONATE-2 study, which compared ibrutinib versus chlorambucil in elderly patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Preliminary data from an ongoing clinical trial suggest ibrutinib has an acceptable safety profile when used to prevent disease progression in patients with asymptomatic, early-stage chronic lymphocytic leukemia.

Acalabrutinib has demonstrated a 95% response rate and durable remissions with a favorable safety profile in a phase I/II study for patients with chronic lymphocytic leukemia.

Jesus San Miguel, MD, PhD, professor of Hematology, medical director of the Clínica Universidad de Navarra, Universidad de Navarra, Pamplona, Spain, discusses the Keynote-023 study, which examined pembrolizumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

Robert Z. Orlowski, MD, PhD, Department Chair ad interim, Department of Lymphoma/Myeloma, Division of Cancer Medicine, professor, Florence Maude Thomas Cancer Research Professorship, The University of Texas MD Anderson Cancer Center, discusses the phase III SWOG 0777 study, which examined the addition of bortezomib to lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with previously untreated multiple myeloma.

Ibrutinib sparks more durable remissions than temsirolimus in patients with relapsed or refractory mantle cell lymphoma.

More than 80% of patients with treatment-refractory Waldenstrom's macroglobulinemia responded to single-agent therapy with ibrutinib, according to results of a preliminary clinical trial.

The addition of pembrolizumab to an established multiple myeloma regimen elicited responses in 76% of 17 patients with relapsed/refractory disease.

Jennifer N. Brudno, MD, medical oncology fellow, National Cancer Institute, discusses a study examining allogeneic T cells expressing an anti-CD19 chimeric antigen receptor (CAR), which was found to cause remissions of B-cell malignancies after allogeneic hematopoietic stem cell transplantation without causing graft-versus-host disease.

Updated findings from early stage clinical trials exploring chimeric antigen receptor-modified T-cell therapies continue to highlight the effectiveness of these approaches for patients with non-Hodgkin lymphoma.

Two-year event-free survival increased from 52% with conventional therapy to 65% with the addition of rituximab among patients with newly diagnosed, CD20-positive Philadelphia (Ph)-chromosome negative B-cell precursor acute lymphoblastic leukemia, according to results from a phase III trial.

Patients with FLT3-mutated acute myeloid leukemia lived significantly longer when treated with the multikinase inhibitor midostaurin compared with placebo.

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Venetoclax, demonstrated an overall response rate of nearly 80% among patients with chronic lymphocytic leukemia harboring the chromosome 17p deletion.

Ibrutinib reduced the risk of death by 84% versus chlorambucil in treatment-naïve elderly patients with chronic lymphocytic leukemia.

More than a third of patients with severe aplastic anemia achieved hematologic responses lasting at least 6 months with the addition of the oral thrombopoietin inhibitor eltrombopag to conventional immunosuppressive therapy.

The addition of daratumumab to a standard multiple myeloma regimen generated responses in 81% of patients with relapsed or refractory disease that were "rapid, deep, and durable" without introducing any new safety concerns.

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the phase III Tourmaline-MM1 study, which compared the efficacy of the addition of ixazomib to lenalidomide and dexamethasone with lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

The addition of idelalisib to bendamustine and rituximab (BR) reduced the risk of progression or death by 67% compared with BR alone for patients with relapsed/refractory chronic lymphocytic leukemia.

An all orally administered treatment regimen containing ixazomib, lenalidomide, and dexamethasone showed a 5.9-month improvement in progression-free survival compared with lenalidomide and dexamethasone alone for patients with relapsed/refractory multiple myeloma.

David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

Genetically engineered T cells eradicated multiple myeloma cells in a patient with advanced disease, suggesting the potential to cure the condition.